Abstract

The potential to use biomarkers for identifying patients that are more likely to benefit or experience an adverse reaction in response to a given therapy, and thereby better match patients with therapies, is anticipated to have a major effect on both clinical practice and the development of new drugs and diagnostics. In this article, we consider current and emerging examples in which therapies are matched with specific patient population characteristics using clinical biomarkers — which we call stratified medicine — and discuss the implications of this approach to future product development strategies and market structures.

Author affiliations

1. Mark R. Trusheim, Ernst R. Berndt and Frank L. Douglas are at the MIT Center for Biomedical Innovation, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139-4307, USA.
   Email: mtrusheim@cobioconsulting.com; Email: eberndt@mit.edu; Email: fldoug@mit.edu

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.